Abstract
We support M.A. Hamburg’s plea for increased funding of regulatory science
(“Advancing regulatory science,” Editorial,
25 February, p. 987). We also share her ambition
to modernize the regulatory system and
bring 21st-century science and technology to
drug development and drug evaluations